Venture Capital Pulse — October 4, 2026
AI dominance continues to define VC markets: Instinct's $1 billion mega-round and EliseAI's $350 million financing lead this week's funding surge, with healthcare and housing tech emerging as hot verticals. Global venture investment is on track to hit $1 trillion in 2026, driven by record exit activity and investor appetite for AI-powered infrastructure. <!-- /headline --> AI Infrastructure Eating Enterprise Software—And Raising Billion-Dollar Rounds <!-- /headline -->
Venture Capital Pulse — October 4, 2026
Top Deals This Week
Instinct — $1,000M Series Unknown
- Sector: AI assistants / consumer AI
- Lead investor(s): Not disclosed
- What they do: Developer of AI assistants for everyday tasks
- Why it matters: Billion-dollar rounds remain rare outside infrastructure and enterprise AI. Instinct's scale signals investor confidence in mainstream AI agent adoption and the willingness to back high-TAM consumer/productivity plays at premium valuations.
news.crunchbase.com
news.crunchbase.com
news.crunchbase.com
The Week’s 10 Biggest Funding Rounds: AI, Energy And Biotech Lead The Way
Global Venture Funding In 2025 Surged As Startup Deals And Valuations Set All-Time Records
EliseAI — $350M Series Unknown
- Sector: AI for housing / proptech
- Lead investor(s): Andreessen Horowitz, Bessemer Venture Partners
- What they do: Deploying AI for the home rental industry
- Valuation: $4 billion
- Why it matters: Real estate tech is emerging as a surprise AI winner. EliseAI's $4B post-money valuation reflects investor belief that vertical-specific AI agents can capture outsized returns in fragmented markets like residential leasing.
Rightway — $155M Growth Equity
- Sector: Healthcare / pharmacy benefits management
- Lead investor(s): Not specified
- What they do: Pharmacy benefits technology platform
- Why it matters: Healthcare continues to attract significant capital. Rightway's $155M growth round signals investor appetite for modernizing legacy healthcare infrastructure through software.
Basalt Health — $20M Series Funding
- Sector: Healthcare tech
- Lead investor(s): Not specified
- What they do: Digital health solutions
- Why it matters: Mid-stage healthcare funding remains robust even as mega-rounds concentrate in AI and infrastructure. Basalt's raise demonstrates diversified investor appetite beyond headline-grabbing billion-dollar deals.
Sector Spotlight
AI Infrastructure & Vertical-Specific AI Driving Capital Concentration
This week's funding flows reveal a clear market bifurcation: AI infrastructure and AI agents for specific verticals (housing, healthcare, enterprise) are absorbing the majority of large checks, while earlier-stage and non-AI startups face tighter capital conditions.
The $1.35 billion deployed across Instinct and EliseAI alone underscores a critical trend: venture investors have identified AI-first solutions to entrenched, analog industries (real estate, pharma, housing) as the next mega-opportunity. Both startups target markets where incumbents have resisted digital transformation, creating a massive TAM for AI-native competitors.
Healthcare tech—represented by Rightway and Basalt—continues to benefit from structural tailwinds (aging populations, regulatory tailwinds, large existing budgets), but is increasingly split: mega-rounds flow to AI-first founders, while traditional health software companies compete for smaller allocations.
Key signal for founders & investors: The "quality" bar has risen sharply. Investors are now screening heavily for:
- Unit economics clarity (the 2023-2025 "growth-at-all-costs" era is definitively over)
- Clear AI differentiation (not just "we added GPT to our product")
- Defensible IP or network effects (training data, proprietary models, or winner-take-most dynamics)
What to Watch Next Week
- $1T global venture milestone: 2026 is on track to cross $1 trillion in total venture funding, a 128% increase over 2025. Watch for celebration posts and think-pieces analyzing whether this signals a market top or a new normal driven by AI.
- Upcoming IPO pipeline pressure: Q3 2026 saw record exit values but historically low distributions to LPs. Expect announcements of delayed IPOs or secondary offerings as portfolio companies navigate a selective public market.
- Healthcare AI M&A: With Rightway and Basalt's funding announced, expect downstream acquisition activity from large health systems and pharmacy benefit managers seeking to acquire AI capabilities rather than build in-house.
- Series B pricing resets: Late-stage rounds may show valuation compression as public comps (Nvidia, etc.) stabilize and mega-round capital becomes scarce outside AI/infrastructure.
Data as of October 4, 2026. Coverage: October 2–4, 2026 only.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
